PTG-100 is under clinical development by Protagonist Therapeutics and currently in Phase I for Celiac Disease. According to GlobalData, Phase I drugs for Celiac Disease does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the PTG-100 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PTG-100 is under development for the treatment of celiac disease. These are disulfide rich peptides and administered orally. The development of the drug candidates are based on the disulfide rich peptides (DRP) technology. The drug candidate antagonize alpha4 beta7 integrin. It was also under development for the treatment of ulcerative colitis.
Protagonist Therapeutics overview
Protagonist Therapeutics (Protagonist) is a clinical-stage biopharmaceutical company that discovers and develops orally stable peptides as targeted therapies. The company through its proprietary technology platform develops structurally novel oral or injectable peptides for protein-protein interaction targets. Protagonist’s peptides specifically target biological pathways that are also targeted by currently marketed injectable antibody drugs. Protagonist’ product candidates are intended for the treatment of inflammatory bowel disease and other gastrointestinal diseases and hematological disorders. The company has its operations in the US and Australia. Protagonist is headquartered in Milpitas, California, the US.
For a complete picture of PTG-100’s drug-specific PTSR and LoA scores, buy the report here.